Spectroscopic Troponin I Detection and Quantification Using Plasmonic Nano-Materials
AssigneeNanosensing Technologies, Inc.
InventorsPatricia Maria Albuquerque de Farias, Arnaldo Cesar Dantas dos Santos Andrade, Josivandro do Nascimento Silva, Jamil Saade
Life of this patent
Estimating the term…
Abstract
A system, and its associated methodology, for detecting cTnl includes a patient sample such as whole blood, serum or plasma, anti-cTnl antibodies conjugated with ligand-capped metallic nanoparticles, and a spectrophotometer operable to detect a shift of wavelength in light resulting from binding of cTnl to the anti-cTnl antibodies conjugated with ligand-capped metallic nanoparticles. By measuring changes in Localized Surface Plasmon Resonance of the anti-cTnl antibodies conjugated with ligand-capped metallic nanoparticles the presence of cTnl can be detected.
Claims31
A method for detecting cardiac-specific Troponin I (cTnI), the method comprising:
- dispersing metallic nanoparticles in an aqueous Cetyl Trimethyl Ammonium Bromide (CTAB) solution forming a plurality of dispersed metallic nanoparticles;
- coating the plurality of metallic nanoparticles with a ligand forming a plurality of ligand-capped metallic nanoparticles wherein a first dispersion containing the plurality of ligand-capped metallic nanoparticles has a pH of substantially 7.0;
- conjugating the plurality of ligand-capped metallic nanoparticles with anti-Troponin I (anti-cTnI) antibodies;
- mixing the anti-cTnI antibodies conjugated with ligand-capped metallic nanoparticles with a patient sample wherein the cTnI within the sample binds with the anti-cTnI antibodies conjugated with ligand-capped metallic nanoparticles wherein a second dispersion containing the plurality of anti-cTnI antibodies conjugated with ligand-capped metallic nanoparticles has a pH of substantially 7.0;
- and
- detecting a presence of cTnI bound to the anti-TnI antibodies conjugated with ligand-capped metallic nanoparticles using a signal generated by Localized Surface Plasmon Resonance (LSPR).
A method for detecting cardiac-specific Troponin I, the method comprising:
- conjugating a ligand-capped metallic nanoparticles with anti-Troponin I (anti-cTnI) antibodies;
- binding one or more anti-cTnI antibodies conjugated with ligand-capped metallic nanoparticles with Troponin (cTnI) from a patient blood sample forming a detection sample;
- and
- responsive to binding one or more anti-cTnI antibodies conjugated ligand-capped metallic nanoparticles with cTnI, detecting in the detection sample a spectral absorption shift in Localized Surface Plasmon Resonance (LSPR) of the metallic nanoparticles confirming a presence of cTnI.
A biosensor comprising cardiac-specific anti-Troponin I (anti-cTnI) antibodies conjugated with polystyrene sulfonate (PSS) capped metallic nanoparticles (MNP).
A system for detecting cardiac-specific Troponin I (cTnI), comprising:
- a patient sample containing cTnI;
- a plurality of anti-Troponin I (anti-cTnI) antibodies conjugated with ligand-capped metallic nanoparticles (MNP);
- and
- a spectrophotometer operable to detect a shift of wavelength in light resulting from binding of cTnI to the anti-cTnI antibodies conjugated with ligand-capped metallic nanoparticles.
Dependencies are inferred from the claim text.